Sells laser systems for cataract surgery and corneal astigmatism treatment to eye surgeons, hospitals and outpatient surgery centers.
Eye-care providers and distributors buy laser systems, patient interface kits and procedure licenses; most customers prepay or pay within 30 days. Direct system sales follow installation and training, distributor system sales are made at shipment, while lease and extended-warranty revenue is earned over the agreement term.
10-K for FY2025, filed Mar 31, 2026The Company principally derives its revenue from the sale and lease of systems and the sale of other related products and services…View ↗
Equipment. The Company’s LLS and ALLY System sales are recognized as Product revenue when the Company transfers control of the system. This…View ↗
PID and Procedure Licenses. The systems require both a PID and a procedure license to perform each procedure. The Company recognizes…View ↗
Service Revenue. The Company offers an extended warranty that provides additional maintenance services beyond the standard limited…View ↗
Lease Revenue. For system operating leases, the Company recognizes lease revenue over the length of the lease in accordance with ASC Topic…View ↗
10-K for FY2025, filed Mar 31, 2026
FY2025 revenue by product or service (Product and service revenue) ↗$58.4M
10-K for FY2025, filed Mar 31, 2026
$58.4M ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Product
Sold outright
10-K for FY2025, filed Mar 31, 2026 |
89%
FY2022: 88%
|
Product, FY2025
$45.9M Sources
|
Sold outright |
|
Service
Recurring
10-K for FY2025, filed Mar 31, 2026 |
11%
FY2022: 12%
|
Service, FY2025
$5.7M Sources
|
Recurring |
In the United States, LENSAR sells directly to ambulatory surgery centers, hospitals and physicians; in Europe, Asia and other targeted international markets, third-party distributors market and sell the systems.
10-K for FY2025, filed Mar 31, 2026
For the year ended December 31, 2025, one customer accounted for 13% of the Company’s revenue and no customers accounted for 10% or more of…View ↗
No. It lost $34.3M in FY2025.
10-Q for Q3 FY2026, filed Nov 10, 2026
−$4.7MView ↗
10-Q for Q3 FY2026, filed Nov 10, 2026
Open tableView ↗
8-K, filed May 29, 2026
On May 25, 2026, the Board of Directors (the “Board”) of LENSAR, Inc. (the “Company”) appointed Michael A. Rossi to serve as the Company’s…View ↗
8-K, filed Apr 15, 2026
On April 10, 2026, Thomas R. Staab, II, Chief Financial Officer of LENSAR, Inc. (the “Company”), notified the Company of his intention to…View ↗
Growing. Revenue grew 70% in 4 years, from $34.5M in FY2021 to $58.4M in FY2025, about 14% a year.
ALLY availability
The older report described an initial launch and planned additional country applications; the latest says ALLY is available to surgeons in the United States and Europe and has clearances in additional countries.
10-K for FY2022, filed Mar 16, 2023 10-K for FY2025, filed Mar 31, 2026We are focused on continuous innovation and continue to develop our proprietary, next generation system, the ALLY System. Our ALLY System…View ↗
We are a commercial-stage medical device company focused on designing, developing and marketing advanced laser systems for the treatment of…View ↗
Competes with Alcon, Bausch + Lomb, Carl Zeiss, AMO, Ziemer Ophthalmic Systems, and KERANOVA
10-K for FY2025, filed Mar 31, 2026We participate in the highly competitive global market for treatments for cataracts. We face significant competition from large…View ↗
Loading...